A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Required: MS4A1 overexpression (CD20+)

histologically confirmed CD20+ lymphoma as documented in the most recent representative pathology report

Required: CD19 expression (CD19+ (only required if prior anti-CD19 therapy))

Patients treated with prior anti-CD19 therapy must have confirmation of CD19 expression in a biopsy done after progression on the last CD19 directed therapy

Must have received: systemic therapy

At least 2 prior lines of systemic therapy including CART or ASCT (up to 4 prior lines of therapy allowed)

Cannot have received: CD3/CD20 bispecific antibody

Exception: Allowed if received as part of frontline therapy for DLBCL and in remission ≥1 year post frontline therapy; or as bridging therapy prior to CAR-T without refractory/progressive disease on BiAb; or in remission ≥6 months after last dose

Prior CD3/CD20 BiAb based therapy with the following exceptions

Cannot have received: tafasitamab (tafasitamab)

Exception: Allowed if received as part of frontline therapy for DLBCL and in remission ≥1 year post frontline therapy; or prior lenalidomide without intolerance or progression

Prior tafasitamab and/or lenalidomide therapy for lymphoma

Cannot have received: lenalidomide (lenalidomide)

Exception: Allowed if received as part of frontline therapy for DLBCL and in remission ≥1 year post frontline therapy; or prior lenalidomide without intolerance or progression

Prior tafasitamab and/or lenalidomide therapy for lymphoma

Cannot have received: allogeneic stem cell transplantation

Prior allogeneic stem cell transplantation

Cannot have received: solid organ transplantation

Prior solid organ transplantation